Mizolastine

Mizolastine is indicated for the symptomatic treatment of allergic conditions, particularly seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria. It helps relieve symptoms including nasal congestion, sneezing, nasal itching, rhinorrhea, itchy eyes, and skin itching associated with allergic reactions.

Mizolastine is a selective and potent histamine H1 receptor antagonist. By competitively blocking H1 receptors in various tissues including the respiratory tract, nasal mucosa, and skin, it prevents histamine from triggering allergic inflammatory responses. This reduces vascular permeability, bronchoconstriction, and other histamine-mediated symptoms.

Mizolastine has been withdrawn from the European market due to concerns about cardiac safety (potential for QT prolongation and arrhythmias). It should not be used in patients with known cardiac disease, electrolyte imbalances, or those taking other medications that affect cardiac conduction. As a non-sedating antihistamine, it causes less drowsiness than first-generation antihistamines, but patients should still be cautious when driving or operating machinery until they know how the medication affects them. Always consult a healthcare provider for personalized medical advice before starting any new medication.